BMY News and Press, Bristol-Myers Squibb Company From 05/15/24

95.7% of patients responded to Breyanzi in the TRANSCEND FL trial Breyanzi provided sustained clinical benefit with median duration of response not reached and the majority (77.1%) of responders in ongoing response at 18 months Breyanzi is a personalized therapy with a...

2024-05-15 19:58:10 ET Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 May 15, 2024 2:20 PM ET Company Participants David Elkins – Executive Vice President and Chief Financial Officer Conference Call Participants Ge...

2024-05-15 17:47:35 ET Tudor Investment Corp. the hedge fund founded by billionaire investor Paul Tudor Jones, took a fresh equity stake in PayPal ( NASDAQ: PYPL ) during Q1 2024, buying about 888K shares, it said in its latest 13F filing dated Wednesday. It also opened a new equity...

2024-05-15 17:36:48 ET More on Bristol-Myers Squibb Bristol-Myers Squibb: A Lost Decade? Bristol Myers Squibb: Tough Times Continue Bristol Myers' Opdivo fails in Phase 3 lung cancer study FDA accepts Bristol Myers application for injected Opdivo Bris...

2024-05-15 08:45:36 ET Summary Pfizer has been a losing investment for several years, but stronger trading momentum is starting to appear. An easily covered and safety-minded 6% dividend yield is very attractive today. Undervaluation arguments to own shares also exist. PFE sto...

2024-05-13 14:23:08 ET Bristol-Myers Squibb Company. (BMY) Guggenheim Securities Radiopharmaceuticals Day May 13, 2024, 11:00 AM ET Company Participants Ben Hickey - President RayzeBio, Head of Mirati Conference Call Participants Presentation Uniden...

2024-05-13 07:58:54 ET Merck ( NYSE: MRK ) has discontinued the vibostolimab and pembrolizumab coformulation arm of a late-stage skin cancer trial .... Read the full article on Seeking Alpha For further details see: Merck discontinues testing of experimental skin...

2024-05-12 04:45:00 ET About once every 90 days, publicly traded companies have to face their shareholders and let them know how their businesses have performed over the past quarter. Those earnings releases often bring with them all sorts of news that can move the market. Sometimes tha...

2024-05-11 07:29:00 ET Bristol Myers Squibb (NYSE: BMY) pays investors an attractive dividend, which yields an incredibly high rate of 5.5%. That's nearly four times the S&P 500 average of 1.4%. At such a high rate, investing approximately $18,200 would be enough to gene...

2024-05-11 06:58:33 ET Summary Organon, Pfizer, and Bristol Myers all offer yields above 5% and can  compete with most Treasuries, but only Organon is up YTD. Spinoffs often struggle in their initial years, but Organon's partial reversal of its decline since Merck's castoff h...